Pfizer (PFE) and Astellas Pharma said long-term follow-up results from a phase 3 clinical trial demonstrated a 30% reduction in the risk of death for men with metastatic hormone-sensitive prostate cancer.
The study, which followed patients for five years, found that treatment with XTANDI plus androgen deprivation therapy improved survival rates compared with placebo plus ADT, the companies said Thursday in a statement.
The data will be presented at the American Society of Clinical Oncology's annual meeting in Chicago on June 3.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。